AIM Vaccine Co., Ltd.'s (HKG:6660) Share Price Boosted 32% But Its Business Prospects Need A Lift Too

Despite an already strong run, AIM Vaccine Co., Ltd. (HKG:6660) shares have been powering on, with a gain of 32% in the last thirty days. Unfortunately, the gains of the last month did little to right the losses of the last year with the stock still down 22% over that time.

Although its price has surged higher, AIM Vaccine may still look like a strong buying opportunity at present with its price-to-sales (or "P/S") ratio of 4.3x, considering almost half of all companies in the Biotechs industry in Hong Kong have P/S ratios greater than 16.1x and even P/S higher than 40x aren't out of the ordinary. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly reduced P/S.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

See our latest analysis for AIM Vaccine

How AIM Vaccine Has Been Performing

With revenue growth that's inferior to most other companies of late, AIM Vaccine has been relatively sluggish. Perhaps the market is expecting the current trend of poor revenue growth to continue, which has kept the P/S suppressed. If you still like the company, you'd be hoping revenue doesn't get any worse and that you could pick up some stock while it's out of favour.

Keen to find out how analysts think AIM Vaccine's future stacks up against the industry? In that case, our free report is a great place to start.

What Are Revenue Growth Metrics Telling Us About The Low P/S?

The only time you'd be truly comfortable seeing a P/S as depressed as AIM Vaccine's is when the company's growth is on track to lag the industry decidedly.

Retrospectively, the last year delivered a decent 8.2% gain to the company's revenues. However, this wasn't enough as the latest three year period has seen an unpleasant 18% overall drop in revenue. Accordingly, shareholders would have felt downbeat about the medium-term rates of revenue growth.

Turning to the outlook, the next three years should generate growth of 62% each year as estimated by the sole analyst watching the company. That's shaping up to be materially lower than the 341% each year growth forecast for the broader industry.

In light of this, it's understandable that AIM Vaccine's P/S sits below the majority of other companies. It seems most investors are expecting to see limited future growth and are only willing to pay a reduced amount for the stock.

The Key Takeaway

Shares in AIM Vaccine have risen appreciably however, its P/S is still subdued. We'd say the price-to-sales ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.

We've established that AIM Vaccine maintains its low P/S on the weakness of its forecast growth being lower than the wider industry, as expected. Right now shareholders are accepting the low P/S as they concede future revenue probably won't provide any pleasant surprises. It's hard to see the share price rising strongly in the near future under these circumstances.

You always need to take note of risks, for example - AIM Vaccine has 1 warning sign we think you should be aware of.

If these risks are making you reconsider your opinion on AIM Vaccine, explore our interactive list of high quality stocks to get an idea of what else is out there.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.